Non-Small Cell Lung Cancer Market, By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Large Cell Neuroendocrine Tumors), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Others), By End User (Hospitals, Homecare, Specialty

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics:

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global non-small cell lung cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

• By Type
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Large Cell Neuroendocrine Tumors
• Treatment
• Chemotherapy
• Targeted Therapy
• Bevacizumab
• Necitumumab
• Ramucirumab
• Immunotherapy
• Nivolumab
• Atezolizumab
• Others
• End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Hoffmann-La Roche Ltd
• Honeywell International Inc.
• AstraZeneca PLC
• Merck & Co., Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Celgene Corporation
• Amgen Inc.
• Johnson & Johnson
• Gilead Sciences, Inc.
• AbbVie Inc.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• Teva Pharmaceutical